×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Merus N.V. Announces Proposed Public Offering of Common Shares
Yahoo Finance
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and...
7 hours ago
Merus announces $300M public offering for clinical developments By Investing.com
Investing.com
UTRECHT, The Netherlands and CAMBRIDGE, Mass. – Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company, has announced a proposed...
7 hours ago
ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody
Pharmaceutical Technology
Shares in Merus rose by 15% in premarket trading, following the announcement of positive Phase II data to be presented at ASCO.
4 days ago
Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and ...
Yahoo Finance
67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28th at 8 a.m. ET UTRECHT, The Netherlands and...
16 hours ago
Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy) (NASDAQ:MRUS)
Seeking Alpha
Merus N.V. is experiencing significant growth and entering a higher price territory, making the risk-reward less clear.
4 days ago
Merus falls on investor concerns over cancer therapy combo trial results
XM
... ** U.S. listed shares of Netherlands-based Merus NV MRUS.O fall 8.5% to about $55. ** Analysts at William Blair said updated interim...
11 hours ago
Merus maintains Buy rating, stock target steady on recent data presentations By Investing.com
Investing.com
Tuesday, Truist Securities reiterated a Buy rating on Merus N.V. (NASDAQ: NASDAQ:MRUS) with a steady price target of $69.00.
10 hours ago
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
AOL.com
Thursday, Merus N.V. (NASDAQ:MRUS) announced the publication of an abstract regarding petosemtamab in combination with pembrolizumab on the...
4 days ago
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
Yahoo Finance
Shares of Merus N.V. MRUS rose 36.2% on Friday after management announced the publication of an abstract for the 2024 ASCO meeting on a...
1 day ago